Experimental Hematology & Oncology

Papers
(The median citation count of Experimental Hematology & Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Complex roles of cAMP–PKA–CREB signaling in cancer225
CD44 as a tumor biomarker and therapeutic target190
Risk factors and outcome of COVID-19 in patients with hematological malignancies112
Research progress on dendritic cell vaccines in cancer immunotherapy71
Role of m6A writers, erasers and readers in cancer70
Engineering better chimeric antigen receptor T cells67
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients66
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC65
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–201763
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition60
Heterogeneity of the tumor immune microenvironment and its clinical relevance59
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies58
Macrophage, the potential key mediator in CAR-T related CRS55
MiRNA-mediated EMT and CSCs in cancer chemoresistance52
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment51
Breast cancer heterogeneity and its implication in personalized precision therapy50
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL47
Recent advances and challenges of bispecific antibodies in solid tumors46
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder43
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia41
COVID-19 vaccination associated severe immune thrombocytopenia38
Current insight into the regulation of PD-L1 in cancer38
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma37
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients36
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development36
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma34
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy33
TRIM family contribute to tumorigenesis, cancer development, and drug resistance33
m6A binding protein YTHDF2 in cancer33
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A433
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors33
Increasing cure rates of solid tumors by immune checkpoint inhibitors31
TCR engineered T cells for solid tumor immunotherapy30
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy30
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma30
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment30
Roles of the intestinal microbiota and microbial metabolites in acute GVHD29
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors29
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 201729
Recent advances in Lynch syndrome29
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas24
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside24
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome23
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis22
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin22
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation22
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 si22
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas22
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China22
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia22
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma21
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer21
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma21
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy20
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review20
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes20
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential19
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio19
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance19
p53 amyloid aggregation in cancer: function, mechanism, and therapy19
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis19
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation18
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy18
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma18
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers18
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy18
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis18
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing17
RHO GTPase family in hepatocellular carcinoma17
Targeting metabolic reprogramming in chronic lymphocytic leukemia17
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion16
Function and clinical significance of N6-methyladenosine in digestive system tumours16
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma16
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner16
The metabolic adaptation mechanism of metastatic organotropism16
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD16
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases15
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce15
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review15
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma15
Recent updates for antibody therapy for acute lymphoblastic leukemia15
Increased TOX expression associates with exhausted T cells in patients with multiple myeloma14
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation14
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression14
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities14
Frontiers in the COVID-19 vaccines development14
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model14
New insight into circRNAs: characterization, strategies, and biomedical applications14
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy14
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia14
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer14
The role of organoids in cancer research14
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP14
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort13
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel13
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment13
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information13
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models13
Targeting phosphoglycerate dehydrogenase in multiple myeloma13
Chimeric antigen receptor engineered natural killer cells for cancer therapy13
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway13
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU12
Targeting NRF2 uncovered an intrinsic susceptibility of acute myeloid leukemia cells to ferroptosis11
Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells11
HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis11
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway11
Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia11
Arsenic trioxide synergistically promotes the antileukaemic activity of venetoclax by downregulating Mcl-1 in acute myeloid leukaemia cells11
Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma11
Profiling of somatic mutations and fusion genes in acute myeloid leukemia patients with FLT3-ITD or FLT3-TKD mutation at diagnosis reveals distinct evolutionary patterns11
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis11
Emerging roles of m6A RNA modification in cancer therapeutic resistance10
Focal adhesion kinase: from biological functions to therapeutic strategies10
MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR10
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target10
Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with defe10
Platelet desialylation and TFH cells–the novel pathway of immune thrombocytopenia10
Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2/c-Myc/RCC1 axis in acute myeloid leukemia9
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies9
CRISPR/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro9
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML9
Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway9
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives9
Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications9
Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model9
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country9
CircRIC8B regulates the lipid metabolism of chronic lymphocytic leukemia through miR199b-5p/LPL axis8
Recent advances and future perspectives in the therapeutics of prostate cancer8
miR-100 inhibits cell proliferation in mantle cell lymphoma by targeting mTOR8
Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting8
Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer8
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy8
Increased expression of ECT2 predicts the poor prognosis of breast cancer patients8
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified8
Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer8
Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect8
The importance of N6-methyladenosine modification in tumor immunity and immunotherapy8
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma8
JOSD2 regulates PKM2 nuclear translocation and reduces acute myeloid leukemia progression8
Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells8
Trends in platelet count among cancer patients7
RNA binding proteins in MLL-rearranged leukemia7
Tregs and GvHD prevention by extracorporeal photopheresis: observations from a clinical trial7
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells7
Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era7
G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway7
Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine7
Low expression of PEBP1P2 promotes metastasis of clear cell renal cell carcinoma by post-transcriptional regulation of PEBP1 and KLF13 mRNA7
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer7
Whole-exome sequencing analysis identifies distinct mutational profile and novel prognostic biomarkers in primary gastrointestinal diffuse large B-cell lymphoma7
Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center7
Calcium oxalate crystals trigger epithelial-mesenchymal transition and carcinogenic features in renal cells: a crossroad between kidney stone disease and renal cancer7
ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer7
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification6
Correction to: Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies6
The emerging roles of SUMOylation in the tumor microenvironment and therapeutic implications6
Immune-related gene index predicts metastasis for prostate cancer patients undergoing radical radiotherapy6
CRISPR/Cas9 system: recent applications in immuno-oncology and cancer immunotherapy6
circRanGAP1/miR-27b-3p/NRAS Axis may promote the progression of hepatocellular Carcinoma6
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide6
Immune checkpoint inhibitors for multiple myeloma immunotherapy6
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era6
Progress in molecular feature of smoldering mantle cell lymphoma6
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia6
Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer6
Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits6
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma6
Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study5
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors5
Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis5
RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation5
Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial5
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development5
Dlk1 maintains adult mice long-term HSCs by activating Notch signaling to restrict mitochondrial metabolism5
The immunometabolic landscape of the bone marrow microenvironment in acute myeloid leukemia5
The gut microbiota as a booster for radiotherapy: novel insights into radio-protection and radiation injury5
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia5
Regulatory T cells contribute to the immunosuppressive phenotype of neutrophils in a mouse model of chronic lymphocytic leukemia5
Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches5
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera5
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia5
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways5
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity5
Deciphering tumor-infiltrating dendritic cells in the single-cell era5
Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/re5
Multiplexed single‐cell mass cytometry reveals distinct inhibitory effects on intracellular phosphoproteins by midostaurin in combination with chemotherapy in AML cells5
Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting5
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells5
ASAP2 interrupts c-MET-CIN85 interaction to sustain HGF/c-MET-induced malignant potentials in hepatocellular carcinoma5
A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways5
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis5
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma5
0.027400016784668